Hiromi Rosselli, MD
Hematology & Oncology · Decatur, GANPI 1174813489
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $442 of the $568 with a category attached, or 77.8%. 14 manufacturers reported payments, led by GSK at 25.0% of the total. Reporting peaked in 2021 at $297 and has fallen 95.0% since, to $15 in 2025. That places this record below the midpoint for hematology & oncology clinicians in GA, where the typical reported total is $4,479.
Across 24 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$142
- Lilly USA, LLC$94
- Novartis$92
- Johnson & Johnson$74
- Deciphera Pharmaceuticals Inc.$44
- Boehringer Ingelheim$21
- plus $100 from 8 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$150
What the payments were for
- Consulting fees$10018%
- Food & beverage$44278%
- Education$265%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $142 |
| Lilly USA, LLC | 1 | $94 |
| Novartis | 4 | $92 |
| Johnson & Johnson | 5 | $74 |
| Deciphera Pharmaceuticals Inc. | 1 | $44 |
| Boehringer Ingelheim | 1 | $21 |
| Bristol Myers Squibb | 1 | $18 |
| Seagen Inc. | 1 | $15 |
| AbbVie | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Merck | 1 | $13 |
| Gilead | 1 | $12 |
| Veracyte, Inc. | 1 | $0 |
How this compares
$568 in reported general payments places this provider in the 20th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $58,076 |
| XareltoRivaroxaban | 12 | $6,699 |
| Exemestane | 18 | $3,385 |
| Anastrozole | 86 | $1,421 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $1,410 |
| Letrozole | 56 | $646 |
| Oxycodone Hcl | 18 | $589 |
| Tamoxifen Citrate | 27 | $350 |
| Prochlorperazine Maleate | 25 | $241 |
| Hydroxyurea | 21 | $174 |
| Dexamethasone | 14 | $102 |
| Ondansetron Hcl | 15 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $74 | $6,69912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Decatur
- David ShepardDecatur$81K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Chandar BhimaniConyers$483K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.